ArticleScientific reports2026
PLX5622 did not alter anxiety-like behaviour and showed limited microglial depletion efficacy in a spinal cord injury model in female rats.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
We previously reported that inflammation, when coupled with motor training following spinal cord injury (SCI) in female rats, promotes neuroplasticity as evidenced by enhanced performance in the trained task. However, this beneficial effect was accompanied by exacerbated anxiety-like behaviours, which are also a recognized consequence of SCI itself. Given that microglia are central mediators of the inflammatory response, their pharmacological ablation may help to clarify their specific role in enhanced motor recovery and their contribution to anxiety exacerbation. To this end, we first aimed to determine the efficacy and impact of the microglia-depleting compound PLX5622 in rats after SCI, as its effects in this traumatic injury model remain poorly characterized. The present study investigated how a four-week PLX5622 diet, started one week post-cervical SCI, influences anxiety-related behaviours, microglial depletion in the central nervous system (CNS), and SCI lesion pathology in adult female Lewis rats. Following the PLX5622 diet, no impact on anxiety-like behaviour was observed. The treatment achieved partial microglial depletion in all CNS regions examined, though to a lesser extent than reported in mice; no microglia morphological changes were detected in the brain or spinal cord. As expected due to delayed treatment, SCI lesion sizes were comparable across groups, but PLX5622-treated rats exhibited a less compact and thinner astrocytic scar at the lesion core. Importantly, our data revealed that PLX5622 also reduces resident macrophage populations in the liver, highlighting that its effects extend beyond the CNS. The limited impact of PLX5622 in our rat model of SCI, together with its lack of microglia specificity, raises concerns about its suitability for isolating microglial contributions to neuroplasticity, particularly regarding anxiety-like behaviour and post-injury motor recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.